Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6789672 | Comprehensive Psychiatry | 2016 | 19 Pages |
Abstract
SA is surprisingly prevalent among non-responders to standard anti-anxiety treatments, and it may represent a novel transdiagnostic target for treatment intervention in this population. Anxiety and global function improved in a small trial of a brief, manualized, attachment-focused psychodynamic psychotherapy, potentially supporting the clinical relevance of attachment dysfunction in this sample. The large decrease in oxytocin levels with treatment, although not statistically significant in this very small sample, suggests the need for further study of oxytocin as a putative biomarker or mediator of SA response. These pilot data generate testable hypotheses supporting an attachment domain underlying treatment-resistant anxiety, and new treatment strategies.
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Barbara Milrod, Margaret Altemus, Charles Gross, Fredric Busch, Gabrielle Silver, Paul Christos, Joshua Stieber, Franklin Schneier,